Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Recombinant IL2RA (Basiliximab Biosimilar) anticorps

Reactivité: Humain, Cynomolgus, Macaque rhésus FACS, BR, IF, IHC, WB Hôte: Human Chimeric unconjugated Recombinant Antibody
N° du produit ABIN5668050
  • Antigène Tous les produits IL2RA (Basiliximab Biosimilar)
    IL2RA (Basiliximab Biosimilar)
    Type d'anticorp
    Recombinant Antibody
    Reactivité
    Humain, Cynomolgus, Macaque rhésus
    Hôte
    • 2
    • 1
    Human
    Clonalité
    • 3
    Chimeric
    Conjugué
    • 3
    Cet anticorp IL2RA (Basiliximab Biosimilar) est non-conjugé
    Application
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    Flow Cytometry (FACS), Blocking Reagent (BR), Immunofluorescence (IF), Immunohistochemistry (IHC), Western Blotting (WB)
    Specificité
    Basiliximab recognises the human IL-2R and binds to the epitope (116)ERIYHFV(122) within the extracellular domain of the CD25 subunit - binding is abolished when 2 or more residues within the epitope are mutated. This epitope overlaps with the interaction site of CD25 and IL-2. CD25 is found in the high-affinity IL-2R (αβγc) - T cells only express CD25 upon activation. IL-2 binding to IL-2R on T cells modulates proliferation and differentiation.
     Réactivité croisée
    Cynomolgus, Macaque rhésus
    Attributs du produit

    OriginalSpeciesName: Human

    OriginalFormat: IgG1

    Purification
    Purified antibody.
    Pureté
    > 98 % as determined by SDS-PAGE
    niveau d'endotoxine
    Endotoxin is < 1.0 EU/mg as determined by the LAL method
    Immunogène
    Basiliximab was prepared by immunizing BALB/c mice with CTC 16 cells.
    Isotype
    IgG1 kappa
  • Indications d'application
    Basiliximab is derived from the murine anti-Tac antibody. For the clinically used format, the variable regions from this antibody were grafted onto the sequence of the human IgG1? constant regions. Basiliximab binding to CD25 competitively blocks the interaction of IL-2R with its ligand IL-2 on the surface of T cells. Blocking this interaction prevents T cell replication and T cell-mediated B cell activation. Basiliximab binding suppresses the immune system inhibits the pathway activating the cellular immune response to allograft rejection. IL-2 signalling suppression can additionally prevent acute graft-versus-host disease, autoimmune disorders and malignancies such as T cell leukemias (Binder et al, 2007). Basiliximab has also been used in FC, IF, IHC and WB studies, which enables the detection of CD25.
    Commentaires

    NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques.

    Restrictions
    For Research Use only
  • Buffer
    PBS with 0.02 % Proclin 300.
    Agent conservateur
    ProClin
    Précaution d'utilisation
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C,-20 °C
    Stockage commentaire
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Antigène
    IL2RA (Basiliximab Biosimilar)
    Abstract
    IL2RA (Basiliximab Biosimilar) Produits
    Synonymes
    anticorps CD25, anticorps IDDM10, anticorps IL2R, anticorps TCGFR, anticorps IL2RAC, anticorps Il2r, anticorps Ly-43, anticorps interleukin 2 receptor subunit alpha, anticorps interleukin 2 receptor, alpha chain, anticorps IL2RA, anticorps Il2ra
    Sujet
    Interleukin-2 receptor subunit alpha, IL-2 receptor subunit alpha, IL-2R subunit alpha, IL-2-RA, IL2-RA, TAC antigen, p55, CD25.
    UniProt
    P01589
Vous êtes ici:
Support technique